ResMed (RMD) Earnings: Q1 Fiscal 2027 Results and Next Report Date

The quarter ended September 30, 2026 and ResMed published the results on October 29, 2026. Revenue and diluted EPS are shown against Q1 fiscal 2026, the same quarter a year earlier, which takes seasonal swings out of the comparison. ResMed reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• ResMed completed the sale of its MatrixCare business on September 1, 2026. MatrixCare's results through that date sit in Residential Care Software, and the gain on the sale is in GAAP other income.
• From Q1 fiscal 2027, ResMed folds restructuring expenses and amortization of acquired intangibles into cost of sales, R&D and SG&A, and reclassified prior periods. The change did not alter previously reported net income or EPS.
• ResMed's fiscal year ends June 30, so Q1 fiscal 2027 is the quarter ended September 30, 2026.

Source: ResMed Q1 fiscal 2027 results, October 29, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How ResMed splits revenue in its own release, under its own labels, for Q1 fiscal 2027 against Q1 fiscal 2026. Indented lines are parts of the line above them.

• ResMed's Sleep and Breathing Health revenue was $1.3 billion in Q1 fiscal 2027, up 8% from $1.2 billion in Q1 fiscal 2026, 89% of total revenue.
• ResMed's Residential Care Software revenue was $155 million in Q1 fiscal 2027, down 7% from $166 million in Q1 fiscal 2026, 11% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q1 fiscal 2027 release, ResMed said:

“Core Constant Currency: 5-7% growth”

“Reported: $5.75-$5.85 Billion”

“Non-GAAP Diluted EPS $12.00-$12.25”

Source: ResMed Q1 FY27 earnings release, Oct 29, 2026.

This is the company's own guidance as of Oct 29, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the RMD forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net revenue and diluted EPS, each as first reported in that quarter's release.

ResMed's next report is expected around January 28, 2027, a date estimated from its reporting history that the company has not yet confirmed. This page will show Q1 fiscal 2027 until those results are out and have been checked against the release.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q1 fiscal 2027 (this page), reported Oct 29, 2026

ResMed sells CPAP and other sleep devices, the masks and accessories that go with them, and software for out-of-hospital care providers. In Q1 fiscal 2027 global sleep devices brought in $716 million and masks and other $540 million of the $1,415 million total, up 9% and 10%. Residential Care Software was $155 million. (ResMed Q1 FY27 earnings release, Oct 29, 2026)

ResMed's Sleep and Breathing Health revenue in the Americas rose to $833 million from $775 million, an increase of 8%, which the 10-Q attributes to increased demand and unit sales of devices and masks. Rest of World rose 8% to $426 million, helped by device fleet renewals in France. (ResMed Form 10-Q, Q1 FY27, Oct 30, 2026)

ResMed's life support device revenue fell 84%, to $4 million from $25 million a year earlier. The 10-Q links the decline mainly to the planned discontinuation of ResMed's Astral device. (ResMed Q1 FY27 earnings release, Oct 29, 2026; ResMed Form 10-Q, Q1 FY27, Oct 30, 2026)

Residential Care Software revenue fell 7% to $155 million because ResMed sold its MatrixCare business on September 1, 2026, for net cash proceeds of $470 million at closing. Excluding MatrixCare, the remaining software businesses, Brightree and MEDIFOX DAN, grew 8%. On a core constant currency basis, which excludes the Noctrix acquisition and the MatrixCare divestiture, total revenue grew 7%. (ResMed Q1 FY27 earnings release, Oct 29, 2026; ResMed Form 10-Q, Q1 FY27, Oct 30, 2026)

ResMed's GAAP diluted EPS of $2.92 was slightly above its non-GAAP EPS of $2.91 because GAAP included the gain on the MatrixCare sale, worth $0.38 a share, which non-GAAP removes. Non-GAAP also adds back amortization of acquired intangibles ($0.07), restructuring and business transformation expenses ($0.16), acquisition and divestment related expenses ($0.07) and the tax effect of interest income on tax refunds ($0.07). (ResMed Q1 FY27 earnings release, Oct 29, 2026)

ResMed repurchased 3.6 million shares at a cost of $855 million in the quarter, including 1.6 million shares under an accelerated share repurchase agreement, against 0.5 million shares for $150 million a year earlier. Diluted shares outstanding fell to 143,411 thousand from 146,899 thousand. (ResMed Form 10-Q, Q1 FY27, Oct 30, 2026; ResMed Q1 FY27 earnings release, Oct 29, 2026)

ResMed's effective tax rate was 22.4%, up from 22.0%, which the 10-Q puts down mainly to global minimum taxes under Pillar Two and discrete tax adjustments. (ResMed Form 10-Q, Q1 FY27, Oct 30, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

ResMed gives a full-year outlook table in its release. For fiscal year 2027 it kept the guidance it set on August 6, 2026: revenue growth of 5-7% on a core constant currency basis, reported revenue of $5.75-$5.85 billion, and non-GAAP diluted EPS of $12.00-$12.25. (ResMed Q1 FY27 earnings release, Oct 29, 2026)

ResMed said it has not reconciled these forward-looking non-GAAP figures to GAAP because the reconciling items cannot be reasonably predicted. (ResMed Q1 FY27 earnings release, Oct 29, 2026)

A consensus figure is the average of the models published by the analysts who cover ResMed, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones ResMed's own release and filings put weight on for Q1 fiscal 2027, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning RMD is on is RMD a buy or a sell?, what analysts expect next is on the RMD forecast, and what the company does is on the ResMed (RMD) stock page.

Every number on this page can be traced to a document ResMed published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.